Compare PCVX & BRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCVX | BRKR |
|---|---|---|
| Founded | 2013 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 7.3B |
| IPO Year | 2020 | 2000 |
| Metric | PCVX | BRKR |
|---|---|---|
| Price | $44.90 | $53.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $101.67 | $49.69 |
| AVG Volume (30 Days) | 1.3M | ★ 1.9M |
| Earning Date | 02-24-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 0.39% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,438,900,000.00 |
| Revenue This Year | N/A | $3.55 |
| Revenue Next Year | N/A | $1.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.10 |
| 52 Week Low | $27.66 | $28.53 |
| 52 Week High | $93.77 | $64.64 |
| Indicator | PCVX | BRKR |
|---|---|---|
| Relative Strength Index (RSI) | 46.03 | 71.67 |
| Support Level | $43.95 | $46.85 |
| Resistance Level | $47.76 | $48.73 |
| Average True Range (ATR) | 1.69 | 1.61 |
| MACD | -0.10 | 0.33 |
| Stochastic Oscillator | 39.85 | 91.88 |
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.